Nuformix plc (LON:NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing, has announced the appointment of Jeffreys Henry LLP as auditor to the Company. The appointment of Jeffreys Henry will be subject to approval by shareholders at the next Annual General Meeting of the Company.
The appointment of Jeffreys Henry follows the resignation of Haysmacintyre LLP who has confirmed to the Company that there are no circumstances connected with its resignation which it considers should be brought to the attention of the members or creditors of the Company. As required by the Companies Act, Nuformix will send a copy of the resignation letter to shareholders.
